We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.02 | -0.82% | 123.00 | 123.77 | 121.2902 | 123.06 | 5,932,928 | 01:00:00 |
From May 2019 to May 2024
LONDON-- Merrion Pharmaceuticals PLC (3MP.DB) said Thursday that drug group Novo Nordisk A/S (NVO) expects to use Merrion's drug delivery technology GIPET in a trial for an insulin tablet.
-Merrion shares unchanged at 10 cents valuing the company at EUR8.3 million.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
